Friday, 21 Jul 2017

You are here

Breastfeeding Rates Lower in Lupus

It is a common practice for rheumatologists to discuss medication-related teratogenicity and disease implications in case of pregnancy.  Yet, discussion of breastfeeding are often omitted.

Besides being after the fact and little known about the safety of breastfeeding, there are few studies of breastfeeding in lupus and most of these are small in size and have other limitations.  This is in stark contrast with the abundance of published studies on lupus and pregnancy.

Breastfeeding is widely promoted in general population for the benefit of both mother and newborn.  But how safe is breastfeeding in SLE patients?  Do we have reasonable, consistent and accurate recommendations to give our lupus patients?

A cross-sectional study done by Acevedo et al involved a group of physicians from Argentina and compared 36 pregnancies (in 31 SLE patients) with the same number of non-SLE controls to retrospectively assess breastfeeding in lupus.

The number of patients not initiating breastfeeding was higher (19%) in lupus compared to non-lupus mothers (5.6%) who opted not to nurse (p value = 0.07).  For those who breastfed, the average duration of breast feeding was 12 months in no-SLE patient as opposed to 6 months in SLE group (p 0.003).

Interestingly, when it came to reasons for weaning, half of the non-SLE mothers thought they breastfed their children for appropriate amount of time (53%), but SLE patients most often weaned bcause of starting lupus-related medications (41%). Lack of breast milk supply was the second most common cause in both groups (24% and 28% respectively).

Analysis of the medications in SLE group showed that majority of the patient who stopped nursing were on low dose corticosteroids or hydroxychloroquine. The authors did not provide any additional data on type or exact dose of steroids and no additional data on other DMARDs.

The study concluded that breastfeeding duration could potentially be optimized by improved patient education in SLE women intending to become pregnant. 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Inflammatory and Autoimmune Diseases are Not Rare in HIV Patients

HIV infection and AIDs has been associated with numerous complications, presumeably resulting from impaired immunity from infection.  Sporadic cases and small cohorts of patients with rheumatic and autoimmune syndromes have been described but epidemiology data on the prevalence is scarce.

Adverse Maternal and Fetal Outcomes in Lupus - and Pre-Lupus Too

A population-based claim study from Sweden has shown that lupus and pre-lupus patients are at risk for adverse maternal and fetal outcomes.   

Cumulative Genetic Hit Hypothesis for Lupus

A recent report in Nature Communications has studied multiple nationalities has shown a "disentangled complex HLA multigenic effect" underlying the genetic basis of systemic lupus erythematosus (SLE).  (Citation source: http://buff.ly/2u623Ht)

Long-Term Additive Cardiovascular Benefit of Plaquenil and Aspirin in Lupus

Systemic lupus erythematosus (SLE) is associated with an increased risk of cardiovascular disease (CVD). The cardioprotective benefits of aspirin (ASA) are well known and the ancillary CV and diabetogenic effects of hydroxychloroquine (HCQ) have also been shown.  A current study in the Journal of Rheumatology has shown that thromboprophylaxis with low-dose ASA and HCQ) yields CVD benefits in SLE.

 

Alveolar Hemorrhage in Lupus Needs Prompt Evaluation

Acute diffuse lung infiltration in patients with systemic lupus erythematosus (SLE) requires prompt evaluation for diffuse alveolar hemorrhage (DAH) when patients have low levels of hemoglobin and complement compound C4 and symptoms of hypoxia. The development of DAH was significantly associated with the presence of these features, South Korean researchers have found.